Remepy

Company Overview

Snapshot

Founded in December 2021 by Or Shoval, Michal Tsur, and Shahar Shelly, Remepy operates with 51–200 employees. The company has raised $61 million across 5 funding rounds from 15 investors. In August 2026, Remepy secured a Series A funding round led by O.G. Venture Partners and M Ventures.

Business overview

Remepy is at the forefront of developing hybrid drugs, aiming to redefine combination therapy and deliver personalized care to patients. The company's core technology involves "Digital molecules," which are mobile applications designed to provide unique digital treatment protocols. These digital molecules incorporate digitized, standardized, and evidence-based interventions to enhance brain plasticity and connectivity, balance the immune system, and drive behavioral changes. Remepy addresses disease endpoints, side effects, and comorbidities, partnering with pharmaceutical companies to integrate its Digital Molecules with traditional drug components. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Pharma & Medical Biotechnology, serving the Pharmaceuticals market.

Strategic signal

Remepy recently announced strong Phase IIa clinical trial results for Hybridopa, its hybrid drug for Parkinson's disease, in May 2026. This positive outcome signals significant progress in validating its hybrid drug approach, demonstrating the potential for combining digital therapeutics with traditional medication to improve patient outcomes. For investors, this indicates a strong clinical pipeline and potential for market disruption in neurological disorder treatments.

Company Intelligence Q&A

What was the most recent funding round for Remepy?

In August 2026, Remepy closed a $36 million Series A financing round. The round was led by O.G. Venture Partners and M Ventures.

What clinical trial results did Remepy announce recently?

In May 2026, Remepy reported strong Phase IIa clinical trial results for Hybridopa, its first-in-class hybrid drug designed for Parkinson's disease.

Did Remepy announce any strategic collaborations recently?

In April 2026, Remepy announced a collaboration with Merck KGaA, Darmstadt, Germany, to advance hybrid drugs across various therapeutic areas. This partnership aims to explore combining medication with app-based therapies in rare tumor programs.

What new evidence did Remepy publish regarding Hybridopa?

In July 2026, Remepy published new mechanistic findings in npj Parkinson's Disease (Nature Portfolio), demonstrating Hybridopa's effect on structural connectivity in the brains of Parkinson's patients, which was associated with improved clinical outcomes.

What was the outcome of Remepy's mobile app study for cognitive decline?

In June 2025, Remepy's mobile app was shown to rewire the brain, modulate the immune system, and improve mood in adults experiencing subjective cognitive decline.